Today, the Global Health Drug Discovery Institute (GHDDI) held a grand event titled "‘AI Kongming’: Pioneering the Future of Drug Discovery" in Beijing, marking the official debut of China's independently - developed AI platform, "AI Kongming".

In the context of the pharmaceutical industry, this platform is a game - changer. It empowers intelligent design across the entire drug development journey. From target analysis, where it helps identify the most promising biological targets for drug intervention, to molecular generation, which creates novel chemical structures with potential therapeutic effects, it covers every crucial step. Additionally, it aids in drug design, ensuring that the molecules are tailored to interact effectively with the target. Activity assessment evaluates how well the designed molecules perform in biological systems, and druggability optimization fine - tunes the molecules to enhance their suitability for clinical development.

This platform has undergone rigorous validation in numerous research pipelines. For instance, in the fight against tuberculosis and malaria, two of the world's most devastating infectious diseases, it has shown remarkable results. The hit rates of candidate molecules, which refer to the proportion of molecules that show promising activity in initial screens, have increased significantly. Moreover, the optimization efficiency, the speed at which molecules can be refined to improve their properties, has been enhanced by several to tens of times compared to traditional drug development processes. This represents a major leap forward in the quest for new and effective drugs.